| COVID 19 all comers | COVID-19 mild to moderate | COVID-19 severe or critically | ||
| COVID 19 hospitalized | COVID 19 all comers | COVID-19 mild to moderate | COVID-19 severe or critically | |
| janus kinase (JAK) inhibitor | ||||
| baricitinib | ACTT-2 ... COV-BARRIER | RECOVERY | Cantini Rodriguez-Garcia | Tziolos COV-BARRIER ... |
| ruxolitinib | Cao DEVENT | |||
| TD-0903 | ||||
| TD-0903 10mg | Singh ... | |||
| TD-0903 1mg | Singh ... | |||
| TD-0903 3mg | Singh ... | |||
| tofacitinib | STOP-COVID ... | Murugesan |
| 6415 | Cantini, 2020 | 2 | 31 | 0 | excluded | not a RCT | risk of bias not avaialble |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
